(Q37509512)

20 August 2017

title

Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer (English)

1 reference

20 August 2017

1 reference

Amer K Karam

1

1 reference

20 August 2017

Jing Wang Chiang

2

1 reference

20 August 2017

Ewina Fung

3

1 reference

20 August 2017

Vladimir Nossov

4

1 reference

20 August 2017

Beth Y Karlan

5

1 reference

20 August 2017

language of work or name

English

0 references

publication date

4 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

114

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

246-252

1 reference

20 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Optimal chemotherapy treatment for women with recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Chemosensitivity and chemoresistance testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Chemotherapy sensitivity and resistance assays: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Secondary cytoreduction for ovarian cancer following cisplatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Critical evaluation of secondary cytoreduction in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Extreme drug resistance is common after prior exposure to paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Gene expression signature with independent prognostic significance in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.02.022

10.1016/J.YGYNO.2009.02.022

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference